James E

Cybin UK/Cybin IRL, London, UK. ellen@cybin.com.

6 papers · 1 preprint · ORCID

ArticleDMT

A short-acting psychedelic intervention for major depressive disorder: a phase IIa randomized placebo-controlled trial.

Erritzoe D, Barba T, Benway T +15

Europe PMC2026
ArticleDMT

Safety, tolerability, pharmacodynamic and wellbeing effects of SPL026 (dimethyltryptamine fumarate) in healthy participants: a randomized, placebo-controlled phase 1 trial.

James E, Erritzoe D, Benway T +12

Europe PMC2023
ArticleDMT

Discovery and <i>In Vitro</i> Characterization of SPL028: Deuterated <i>N</i>,<i>N</i>-Dimethyltryptamine.

Layzell M, Rands P, Good M +5

Europe PMC2023
ArticleDMT

Pharmacokinetics of N,N-dimethyltryptamine in Humans.

Good M, Joel Z, Benway T +9

Europe PMC2023
PreprintDMT

PHARMACOKINETICS OF N,N-DIMETHYLTRYPTAMINE FUMARATE IN HUMANS

Good M, Benway T, Joel Z +9

Europe PMC2022
ArticleAyahuasca

Reply to: 5-MeO-DMT has not been found in traditional ayahuasca preparations and the combination of 5-MeO-DMT with MAOIs is dangerous.

James E, Keppler J, Robertshaw TL +1

Europe PMC2022
ArticleAyahuasca

N,N-dimethyltryptamine and Amazonian ayahuasca plant medicine.

James E, Keppler J, L Robertshaw T +1

Europe PMC2022